Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NVS shares declined on 4/9/19 by the implied value of the ALC spin-off (0.2 shares of ALC for each share of NVS) because that was the day the ALC spin-off went ex-dividend.
I don't understand what you're referring to by the "150% orbit."
I'm not sure how well Mayzent (the new MS drug) will sell.
Higher PE sounds sweet
But if Alcon was an earnings dog, why did the stock price go into orbit 150% and NVS got hammered by about an extra $15 after it gave up Alcon??
The lower price and no reduction in the dividend, and stock buy back and CEO forward guidance all look like a buy down this low.
Is the MS Drug news a good thing or way down the pike?
I am catching up all the news right now, still reading....
I would think that the NVS balance sheet might have shed some Alcon long term liabilities and debt?
The ALC spin-off did not benefit NVS itself except in the sense that it removed a business segment growing more slowly than the rest of NVS.
NVS hopes that this will result in a higher P/E ratio.
p.s. Thanks for your kind words.
DD, do you know what if anything NVS got out of the Alcon IPO spin off?
Reduced debt?
Did NVS sell any Alcon shares and thus raise cash?
I know NVS shareholders got Alcon shares, and they exploded in price in 24 hours.
I presume NVS gave revenue and some profit in the Alcon spin off, so why did they do they spin off since shareholders of NVS got the shares???
Thought maybe you had run across the answer in your awesome DD
Seem to be a lot of moving parts in this company already this year.
Still long here.
NVS completes separation of Alcon, which is now trading as ALC on the NYSE.
NVS was -12% today because it was the ex-dividend date for the Alcon spin-off.
https://www.novartis.com/news/media-releases/novartis-plans-alcon-spin-april-9-2019
NVS sues AMGN re Aimovig collaboration termination:
https://www.reuters.com/article/us-amgen-novartis-lawsuit/novartis-sues-amgen-over-migraine-treatment-aimovig-idUSKCN1RG21I
FDA approves NVS’ Mayzent* for MS—including SPMS:
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm634469.htm
a/k/a siponimod, BAF312.
If NVS Does BO AMRN,
This board will become very active ))
WSJ opines on the “new” Novartis:
https://www.wsj.com/articles/novartis-ceo-bets-on-cutting-edge-science-to-remake-drug-giant-1542629461
NVS R&D Day slides (170 pages):
https://www.novartis.com/sites/www.novartis.com/files/2018-11-r-d-day-investor-presentation.pdf
PFE-NVS clinical-trial collaboration in NASH: #msg-144519047.
NVS receives CRL for Ilaris in CVD: #msg-144301592.
AMGN, NVS launch Humira biosimilars in Europe, pursuant to prior settlements with ABBV (#msg-134970085, #msg-144157243):
https://uk.reuters.com/article/us-abbvie-biosimilars/amgen-novartis-kick-off-fight-for-abbvie-blockbuster-drug-in-eu-idUKKCN1MQ1QT
Two additional Humira biosimilars—from MYL and Samsung—are expected to launch in Europe soon.
No pricing information on Humira biosimilars in Europe has been publicly disclosed yet.
The formulation and method-of-use patents that ABBV has used to keep Humira biosimilars off the market in the US until 2023 did not stand up to challenge in Europe.
ABBV settles global Humira-patent litigation with NVS: #msg-144157243.
PDUFA date for NVS’ BAF312 in SPMS—>Mar 2019 (with priority review voucher):
https://globenewswire.com/news-release/2018/10/08/1617727/0/en/Novartis-announces-FDA-and-EMA-filing-acceptance-of-siponimod-the-first-and-only-drug-shown-to-meaningfully-delay-disability-progression-in-typical-SPMS-patients.html
In the EU, an MAA has been submitted, and regulatory action is expected in late 2019.
Entresto will flop
All they've done is capitalize on the benefits of switching someone with CHF and COPD from and ACE inhibitor to an ARB, any ARB.
These days pretty much everyone with CHF also has COPD.
They are using a massive marketing campaign with many TV commercials to try and convince people that Entresto is something new when it's mainly comprised of the same drug (valsartan) that was their once big time seller they called DIOVAN, they recently lost patent protection on.
Their trial did not include a true head to head comparison of valsartan vs valsartan/sacubitril.
They try and convince people that using an ARB instead of an ACE inhibitor for CHF is something new, ARB's have been around for years and there are many examples from many companies.
Doctors and insurance companies will soon get wise to this and Entresto sales will plummet.
Never before in history has a pharma tried such an attempt at repackaging and re-patenting a drug that they lost patent protection on in this manner, people will catch on eventually.
NVS sells US small-molecule-generics business to India’s Aurobindo for $900M plus $100M in contingent payments:
https://in.reuters.com/article/us-novartis-sandoz-aurobindo-pharma/novartis-sells-u-s-generics-assets-to-indias-bargain-hunting-aurobindo-idINKCN1LM0D4
Such a low price for this business would have been unthinkable a few years ago.
NVS reports soft 2Q18—but re-iterates full-year guidance:
https://www.wsj.com/articles/novartis-backs-2018-outlook-after-sales-grow-1531892742
NVS seeks to divest Alcon—will take enormous loss relative to $50B (cumulative) acquisition price:
https://www.bloomberg.com/news/articles/2018-06-29/novartis-to-spin-off-alcon-buy-back-up-to-5-billion-of-stock
Entresto is nothing more than an attempt by Novartis to extend the patent life of Diovan (Valsartan). There is nothing to prove that Entresto is any better than the now generically available Valsartan.
There are other things to watch for with regards to Novartis integrity, such as making facilities managers from a failed pump and dump like ArQule into an "automation guru". There are so many highly qualified people in the industry to choose from for such roles yet they hired a "facilities manager", how embarrassing, these pharmaceutical companies don't even make an honest effort anymore.
NVS slides from “Meet the Management” Investor Day:
https://www.novartis.com/sites/www.novartis.com/files/2018-05-meet-the-management-group-presentation.pdf
Data support 12-week dosing of RTH258 for some wet-AMD patients: #msg-140425036.
FDA approves Tafinlar/Mekinist for adjuvant BRAF-V600+ melanoma:
https://globenewswire.com/news-release/2018/04/30/1490316/0/en/Novartis-receives-FDA-approval-of-Tafinlar-Mekinist-for-adjuvant-treatment-of-BRAF-V600-mutant-melanoma.html
NVS acquires AVXS for $8.7B in cash:
https://www.sec.gov/Archives/edgar/data/1114448/000117184318002601/f6k_040918.htm
NVS PR on consumer-JV sale to GSK:
https://www.sec.gov/Archives/edgar/data/1114448/000117184318002301/f6k_032718.htm
NVS seeking bids for US small-molecule-generics business:
https://www.reuters.com/article/us-novartis-genericdrugs/novartis-readies-to-auction-u-s-generic-pills-business-sources-idUSKCN1G01SW
FoBs and “complex” generics such as Copaxone are not part of the planned divestiture.
Go baby go!!!! $NVS
NVS 4Q17 results…
PR:
https://www.sec.gov/Archives/edgar/data/1114448/000137036818000004/a180124-99_1.htm
Supplementary financial tables:
https://www.sec.gov/Archives/edgar/data/1114448/000137036818000004/a180124-99_2.htm
CC slides:
https://www.novartis.com/sites/www.novartis.com/files/q4-2017-ir-presentation.pdf
Novartis been researching PS Phosphatidylserine targeting ?
Drug: MBG453
MBG453 is a high-affinity, humanized anti-TIM-3 IgG4 monoclonal antibody which blocks the binding of TIM-3 to phosphatidylserine (PtdSer).
David Epstein bring Jay Bradner and Glenn Dranoff over from Dana Farber to further pursue PS Targeting combinations ?
Novartis Glenn Dranoff been researching PS Targeting and Novartis requires that expertise yesterday, though will Novartis secure all rights? One hell of a week coming up to find out
https://www.nibr.com/stories/discovery/new-recruit-has-big-dreams-cancer-immunotherapy
The market is overvalued and overbought, and 2018's lower tax rates will provide the opportunity to take some profits. A correction is likely to begin next week.
NVS’ Investor Day PR and slides:
https://globenewswire.com/news-release/2017/11/13/1184851/0/en/Novartis-highlights-its-differentiated-late-stage-pipeline-at-the-R-D-update-and-investor-event.html
https://www.novartis.com/sites/www.novartis.com/files/2017-11-r-d-day-investor-presentation.pdf
NVS sees its “big-4” prospects as RTH258 (#msg-136129447); AMG 334/Erenumab (#msg-132026403); Cosentyx (#msg- 123968598); and Ilaris/ACZ885/Canakinumab (#msg-136163917).
NVS reports full dataset for RTH258-vs-Eylea phase-3 trials: #msg-136129447.
NVS submits Kymriah BLA in adult DLBCL: #msg-135827815.
NVS acquires AAAP for $82/ADS: #msg-135797034.
Merging CRISPR editing and single cell sequencing technologies to uncover the biology of human neuro development diseases. Exciting talk by Novartis Institute for Bio Medical Research at SMi's London Summit on 3D Cell Culture by Max Salick! http://www.3D-CellCulture.com/i
OK, thanks, also looks like it was a very low volume premarket hit (shorts?) and now in the regular market it is bouncing with some large block buys. But no idea if the Europe market reacted first.
NVS delayed the potential Alcon spin-off until 2019.
Why the big drop in NVS today?
Vasant Narasimhan becomes CEO 2/1/18—succeeding Joe Jimenez: #msg-134366063.
Kymriah/CAR-T outcomes-based pricing: #msg-134254831.
FDA approves NVS’ Kymriah (CTL019 CAR-T) for pediatric ALL:
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm
New drug from Novartis helps prevent heart attacks by curbing inflammation
For the first time, a drug has helped prevent heart attacks by curbing inflammation, a new and very different approach than lowering cholesterol, the focus for many years.
Read more: https://www.cnbc.com/2017/08/27/a-first-drug-lowers-heart-risks-by-curbing-inflammation.html
Followers
|
18
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
430
|
Created
|
06/12/09
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |